Portal de Periódicos da CAPES

Biomarkers for Adverse Events Associated with Immune Checkpoint Inhibitors

2016; Future Medicine; Volume: 10; Issue: 10 Linguagem: Inglês

10.2217/bmm-2016-0211

1752-0371

Hampig Raphaël Kourié, Marianne Paesmans, Jean Klášterský,

Melanoma and MAPK Pathways

Biomarkers in MedicineVol. 10, No. 10 EditorialBiomarkers for adverse events associated with immune checkpoint inhibitorsHampig Raphael Kourie, Marianne Paesmans & Jean KlasterskyHampig Raphael Kourie*Author for correspondence: E-mail Address: hampig.kourie@bordet.be Medical Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium, Marianne Paesmans Unité de Gestion de l'Information, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium & Jean Klastersky Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Université Libre de Bruxelles, Brussels, BelgiumPublished Online:14 Sep 2016https://doi.org/10.2217/bmm-2016-0211AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: biomarkerscheckpoint inhibitorscytokineseosinophilsgenetic predispositionpredictiontoxicityReferences1 Kourie HR, Klastersky J. Immune checkpoint inhibitors side effects and management. Immunotherapy 8(7), 799–807 (2016).Link, CAS, Google Scholar2 Kourie HR, Klastersky JA. Side-effects of checkpoint inhibitor-based combination therapy. Curr. Opin. Oncol. 28(4), 306–313 (2016).Crossref, Medline, CAS, Google Scholar3 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).Crossref, Medline, CAS, Google Scholar4 Jaber SH, Cowen EW, Haworth LR et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch. Dermatol. 142(2), 166–172 (2006).Crossref, Medline, CAS, Google Scholar5 Schindler K, Harmankaya K, Kuk D et al. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. J. Clin. Oncol. 32(5s), Abstract 9096 (2014).Google Scholar6 Tarhini AA, Zahoor H, Lin Y et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 15(3), 39 (2015).Crossref, Google Scholar7 Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug. Discov. 11(10), 763–776 (2012).Crossref, Medline, CAS, Google Scholar8 Shahabi V, Berman D, Chasalow SD et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J. Transl. Med. 22(11), 75 (2013).Crossref, Google Scholar9 Valpione S, Pasquali S, Campana L et al. Predictors of toxicity for metastatic melanoma patients treated with ipilimumab. J. Immunother. Cancer 3(Suppl. 2), 247 (2015).Crossref, Google Scholar10 Clinical Trials Database: NCT02600143. https://clinicaltrials.gov/ct2/show/NCT02600143.Google ScholarFiguresReferencesRelatedDetailsCited ByTargeting Inhibition of Foxp3 by MMP2/9 Sensitive Short Peptide Linked P60 Fusion Protein 6(P60‐MMPs) to Enhance Antitumor Immunity25 May 2020 | Macromolecular Bioscience, Vol. 20, No. 7Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice22 March 2018 | Frontiers in Oncology, Vol. 8Informatics for cancer immunotherapyAnnals of Oncology, Vol. 28Negative predictive biomarkers of checkpoint inhibitors in hyper-progressive tumorsKhalil Saleh, Nadine Khalife-Saleh, Elias El Haddad & Hampig Raphael Kourie4 October 2017 | Biomarkers in Medicine, Vol. 11, No. 10The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectivesHampig Raphael Kourie, Gil Awada & Ahmad Awada27 June 2017 | Immunotherapy, Vol. 9, No. 8 Vol. 10, No. 10 Follow us on social media for the latest updates Metrics Downloaded 168 times History Published online 14 September 2016 Published in print October 2016 Information© Future Medicine LtdKeywordsbiomarkerscheckpoint inhibitorscytokineseosinophilsgenetic predispositionpredictiontoxicityFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download